Lasofoxifene

• Description :

  Lasofoxifene (CP-336156) is an orally active and selective estrogen receptor modulator (SERM) . Lasofoxifene exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene can be used for research of breast cancer and postmenopausal osteoporosis[1][2].

• CAS Number :

  [180916-16-9]

• Product Name Alternative :

  CP-336156

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H312, H332

• Target :

  Estrogen Receptor/ERR

• Type :

  Reference compound

• Related Pathways :

  Vitamin D Related/Nuclear Receptor

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/lasofoxifene.html

• Purity :

  99.27

• Solubility :

  DMSO : 9.09 mg/mL (ultrasonic; adjust pH to 4 with 1 M HCl)

• Smiles :

  OC1=CC=C2[C@@H](C3=CC=C(OCCN4CCCC4)C=C3)[C@@H](C5=CC=CC=C5)CCC2=C1

• Molecular Formula :

  C28H31NO2

• Molecular Weight :

  413.55

• Precautions :

  H302, H312, H332

• References & Citations :

  [1]Lainé M, et al. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021 May 12. 23 (1) :54. |[2]Andreano KJ, et al. The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor. Mol Cancer Ther. 2020 Jul. 19 (7) :1395-1405. |[3]Andersson A, et al. Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis. Rheumatology (Oxford) . 2016 Mar;55 (3) :553-63.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Citation 01 :

  NPJ Breast Cancer. 2022 Dec 14;8 (1) :130.|NPJ Breast Cancer. 2025 Nov 12;11 (1) :125.|bioRxiv. 2024 Jun 2:2024.05.28.596307.|Gynecol Oncol. 2019 Jul;154 (1) :199-206.|Mol Cancer Ther. 2020 Jul;19 (7) :1395-1405.